DrugDashboards

Methylphenidate Hydrochloride

Methylphenidate Hydrochloride · METHYLPHENIDATE HYDROCHLORIDE 27 mg/1 · Tablet, Extended Release · Oral · American Health Packaging

NDC 60687-0543-21 · 30 BLISTER PACK in 1 BOX, UNIT-DOSE / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK · ANDA · View full market →

The short version

12 companies supply this market — deep enough that no single failure threatens the supply. The generic price is down 9% over the past year, to $0.6446 per unit. The brand (Concerta) runs $12.72 per unit 19× more. It is in shortage right now — FDA lists the reason as “demand increase for the drug. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.6446per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicaid generic ceiling (FUL)$2.13per TABweighted avg manufacturer price $1.2172 · Aug 1, 2026330% of what pharmacies pay — higher than 95% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 31722-0953-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$2.16per unit
middle half $1.26$3.50 · 1,637 plans · Apr 1, 2026
Est. net of rebates
≈ $2.16
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
30%of plans cover it
tier 4 · prior auth 4% · step therapy 0% · qty limit 69%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.50$5.00$7.50Aug 2020Sep 2026$0.6446
59 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$19.34
#90 count
$58.01

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Supply fragility

15Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • related presentation in shortage+15

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for methylphenidate hydrochloride (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA211009
TE code
AB
Approval date
Sep 3, 2019
Patents / exclusivity
None on file

Shortage history

  • In shortage now Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Methylphenidate Hydrochloride (Tablet, Extended Release)

LabelerStrengthFirst seenLast seen
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Dr.Reddys Laboratories IncMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Granules Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Granules Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Northstar Rx LLCMETHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.METHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 45 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 63 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
Vertical Pharmaceuticals, LLCMETHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
Vertical Pharmaceuticals, LLCMETHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Vertical Pharmaceuticals, LLCMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Methylphenidate Hydrochloride — NDC 60687-0543-21," retrieved September 3, 2026, https://drugdashboards.com/drug/60687054321.

Free to cite with attribution — see how the data is put together.